
Quick Access
Pre-Congress Hands-on Workshop
October 7, 13:00 – 17:30
An exclusive hands-on workshop experience led by industry experts.
Programme
Explore the sessions
Programme Booklet
Look beyond the programme. The booklet has a few surprises tucked between the sessions, speakers and science.
As you browse, keep an eye out for Epithelix fun facts, anniversary moments, Easter eggs and other details celebrating 20 years of innovation.
Some are easy to spot. Others… you might have to look a little closer.
Happy exploring!
Programme at a glance
Browse the schedule by category.
Day 1 – Main Congress
Thursday, 8 October 2026
Registration
Arrival of participants in the venue and poster hanging
Beyond "Human-Relevant": Decision-Relevant Inhalation Toxicology by Design
Dr. Shaun D. McCullough
LinkedInTeam Lead and Senior Principal Scientist, Predictive Toxicology and Exploratory Biology, RTI International
Long-term in vitro exposure of an air-liquid interface immunocompetent tri-culture human bronchial cell model to traffic-related ambient air
Dr. Mathilde Delaval
LinkedInResearch team leader, Helmholtz Munich / Lung Health and Immunity institute
A Hypothesis-driven Framework for Screening Potential Respiratory Sensitizers
Research Institute for Fragrance Materials (RIFM)
Coffee Break, Visiting Exhibition Area, Poster Viewing
From Mechanistic Insights to Antiviral Discovery: over a Decade of Respiratory Virus Research in Human Airway Epithelia
Prof. Caroline Tapparel
LinkedInProfessor, Medical faculty, University of Geneva
Long-term inflammatory consequences of SARS-CoV-2 infection
Sang Hyun (Ryan) Chun (M.S)
LinkedInPh.D. Student, Graduate School of Biomedical Sciences, University of Texas Health Science Center, San Antonio
Development of a PBMC-bronchial MucilAir™ co-culture model to decipher asthma exacerbation mechanisms induced by Respiratory Syncytial Virus infection
Dr. Pereira De Oliveira
LinkedInResearcher, International Research Laboratory RespiVir France-Canada, CIRI- Centre International de Recherche en Infectiologie, Faculté de Médecine RTH Laennec
Lunch Break, Visiting Exhibition Area, Poster Viewing
An autologous human iPSC-derived multicellular Alveolus-on-Chip reveals early pathological events of M. tuberculosis infection
Dr. Jakson Luk
LinkedInResearcher, Laboratory of Host-Pathogen Interactions in Tuberculosis, The Francis Crick Institute
Mechanistic insights into the early stage of Bordetella pertussis respiratory infection using fully-differentiated human nasal epithelial cells
Dr. Nathalie Mielcarek
LinkedInDeputy Director, Center for Infection and Immunity of Lille
A Primary Human ALI Infection Model with Bioluminescent MDR Pathogens for Real-Time Antimicrobial Efficacy Assessment
Dr. Marc Vandamme
LinkedInR&D program manager, ERBC Group
Coffee Break, Visiting Exhibition Area, Poster Viewing
Advanced in vitro and ex vivo models for the development of respiratory therapeutics
PD Dr. Katherina Sewald
LinkedInDivision Co-Director of Preclinical Pharmacology and Toxicology, Fraunhofer Institute for Toxicology and Head of Department of Pre-clinical Pharmacology & Infection and Immunology, Experimental Medicine (ITEM).
Patient-Derived Airway Organoids for Modelling COPD
Miss Serena Bateman (BSc)
LinkedInScientist, Complex In Vitro Models, Human Biology, GlaxoSmithKline (GSK)
Adopting and deploying the precision-cut lung slice model for airway constriction studies – challenges, pitfalls, and lessons learned
Prof. Ynuk Bossé
Professor, Faculty of Medicine, Université Laval
PSCI X Epithelix Awardee Announcement
Closure of Day 1
Departure to Sunset Dinner Experience at Panoramiques du Salève from the Conference Center
Meet our keynote speakers

Dr. Shaun D. McCullough
Team Lead and Senior Principal Scientist, Predictive Toxicology and Exploratory Biology
RTI International
Senior Respiratory Scientist leading human-relevant in vitro inhalation toxicology and respiratory biology programs. Research advances in vitro model development, mechanistic toxicology, and experimental exposure methods to support regulatory decision-making.

Prof. Caroline Tapparel
Professor
Medical Faculty, University of Geneva
Specialist in molecular virology and the pathogenesis of respiratory and neurotropic viruses, with research focusing on virus–host interactions, viral diversity, and mechanisms of virulence and tissue tropism to support the development of broad-spectrum antiviral strategies.

Dr. Jakson Luk
Researcher
Laboratory of Host-Pathogen Interactions in Tuberculosis, The Francis Crick Institute
Postdoctoral training with Max Gutierrez on molecular strategies to study host–pathogen interactions in tuberculosis. Established a human iPSC-derived alveolus-on-chip platform modelling respiratory infections and lung diseases.

PD. Dr. Katherina Sewald
Division Co-Director, Preclinical Pharmacology and Toxicology
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Division Co-Director of Preclinical Pharmacology and Toxicology, Fraunhofer Institute for Toxicology and Head of Department of Pre-clinical Pharmacology & Infection and Immunology, Experimental Medicine (ITEM).

Prof. Olivier Guenat
Professor of Biomedical Engineering
Bern University
Head of Organs-on-Chip Technologies at ARTORG Center, developing lung-on-chip models mimicking healthy and diseased lung microenvironments. Founder of AlveoliX biotech startup, with prior roles at Harvard Medical School, CSEM, and École Polytechnique de Montréal.

Dr. Clive Roper
Director
Roper Toxicology Consulting Limited
Consultant toxicologist with 30+ years developing animal-free in vitro models for skin, dermal, and respiratory toxicology testing. Founder of Roper Toxicology Consulting, VP of ESTIV, and board member of NC3Rs, US 3Rs Collaborative, and PeptiMatrix.

Dr. Lydia Esteban Enjuto
CTO
MucFlow
Scientist and R&D leader specialising in multi-scale rheology of pathological pulmonary mucus. Expertise spanning biophysical characterisation, scientific application management, and the study of therapeutic proteins in drug reconstitution devices.

Dr. Lauriane Cabon
Group Lead, Applied Organoid Technologies
Institute of Human Biology (IHB), Roche
Leads translational efforts converting organoid platforms into robust assays supporting drug development and therapeutic discovery. Advances human in vitro models across disease modelling, immunology, and oncology to bridge preclinical evidence.
Sponsors
Discover our sponsors and exhibiting companies
Platinum
Our Platinum Sponsors

emka TECHNOLOGIES
emka TECHNOLOGIES develops advanced solutions for preclinical physiological monitoring, with a strong focus on respiratory, cardiovascular, and neurological function. Their instrumentation and data acquisition systems support toxicology and safety pharmacology research, making them a trusted partner for scientists working at the interface of in vivo and in vitro respiratory science.

Epithelix
Epithelix is a Swiss biotech company and the organiser of LIVe2026. For 20 years, Epithelix has been developing ready-to-use primary human airway tissues, including nasal, bronchial, small-airway, and alveolar models — with immunocompetent variants. Their MucilAir™, SmallAir™, and AlveolAir™ tissue systems are reference models in the field, used globally for drug efficacy testing, inhalation toxicology, and respiratory infection research. Epithelix also provides CRO services for a broad range of respiratory applications.

Precisionary Instruments
Precisionary Instruments specialises in tissue sectioning technology, notably the Compresstome® vibrating microtome. Their patented compression technology enables the consistent production of high-quality precision-cut lung slices (PCLS), a key model type in in vitro respiratory research. The Compresstome® is widely used across lung, brain, and other tissue applications in both academic and industry settings.

VITROCELL Systems GmbH
VITROCELL specialises in in vitro exposure technology, notably its air/liquid interface exposure systems for inhalation toxicology and skin testing. Its patented modules enable the precise, reproducible exposure of cell cultures to aerosols, gases, and smoke, a key capability for in vitro respiratory and dermal research. VITROCELL's systems are widely used across lung, skin, and other tissue applications in both academic and industry settings.
Exhibitor
Companies showcasing at the congress

AlveoliX
AlveoliX develops advanced in vitro human alveolar and lung barrier models, enabling physiologically relevant studies of lung function, drug delivery, and inhalation toxicology.

HiLung Inc
HiLung develops human iPSC-derived respiratory cells, organoids, and disease models to accelerate respiratory drug discovery and safety research. Its human-relevant platforms support applications ranging from pulmonary toxicity and infectious disease research to the development of New Approach Methodologies.

INVITROLIZE
INVITROLIZE develops advanced human-relevant in vitro models for respiratory toxicology. Its patented ALIsens® 3D alveolar model enables the identification and differentiation of respiratory sensitizers and irritants under realistic air–liquid interface conditions, supporting more predictive and animal-free safety assessment.

STEMCELL Technologies
STEMCELL Technologies provides standardized, high-quality cell culture media, reagents, and tools for life science research, supporting the isolation, culture, and analysis of primary respiratory and immune cells.
Digital
Our online partners

PETA Science Consortium International e.V.
PETA Science Consortium International advances reliable, human-relevant non-animal approaches to toxicology. Through research funding, scientific collaboration, training, and regulatory engagement, PSCI supports the development and adoption of alternative methods, including approaches for respiratory and inhalation toxicity.
Notifications
Stay updated with the latest congress announcements
All caught up!
No new notifications at the moment. Check back later for updates.
Stay Informed
Important announcements about schedule changes, keynote reminders, and workshop updates will appear here. Check back regularly during the congress for real-time updates.